Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS.

Engel S, Friedrich M, Muthuraman M, Steffen F, Poplawski A, Groppa S, Bittner S, Zipp F, Luessi F.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 19;6(5). pii: e595. doi: 10.1212/NXI.0000000000000595. Print 2019 Sep.

2.

Selective Brain Network and Cellular Responses Upon Dimethyl Fumarate Immunomodulation in Multiple Sclerosis.

Ciolac D, Luessi F, Gonzalez-Escamilla G, Koirala N, Riedel C, Fleischer V, Bittner S, Krämer J, Meuth SG, Muthuraman M, Groppa S.

Front Immunol. 2019 Jul 30;10:1779. doi: 10.3389/fimmu.2019.01779. eCollection 2019.

3.

[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany].

Bittner S, Engel S, Lange C, Weber MS, Haghikia A, Luessi F, Korn T, Klotz L, Bayas A, Paul F, Heesen C, Stangel M, Wildemann B, Bergh FT, Tackenberg B, Trebst C, Warnke C, Linker R, Kerschensteiner M, Zettl U, Tumani H, Brück W, Meuth SG, Kümpfel T, Hemmer B, Wiendl H, Gold R, Zipp F.

Nervenarzt. 2019 Jul 11. doi: 10.1007/s00115-019-0760-0. [Epub ahead of print] Review. German.

PMID:
31297574
4.

Author Correction: A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis.

International Multiple Sclerosis Genetics Consortium.

Nat Commun. 2019 Jul 1;10(1):2956. doi: 10.1038/s41467-019-10951-1.

5.

Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk.

International Multiple Sclerosis Genetics Consortium. Electronic address: chris.cotsapas@yale.edu; International Multiple Sclerosis Genetics Consortium.

Cell. 2019 Jun 27;178(1):262. doi: 10.1016/j.cell.2019.06.016. No abstract available.

6.

Fatigue in SLE: diagnostic and pathogenic impact of anti-N-methyl-D-aspartate receptor (NMDAR) autoantibodies.

Schwarting A, Möckel T, Lütgendorf F, Triantafyllias K, Grella S, Boedecker S, Weinmann A, Meineck M, Sommer C, Schermuly I, Fellgiebel A, Luessi F, Weinmann-Menke J.

Ann Rheum Dis. 2019 Sep;78(9):1226-1234. doi: 10.1136/annrheumdis-2019-215098. Epub 2019 Jun 11.

PMID:
31186256
7.

A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis.

International Multiple Sclerosis Genetics Consortium.

Nat Commun. 2019 May 20;10(1):2236. doi: 10.1038/s41467-019-09773-y. Erratum in: Nat Commun. 2019 Jul 1;10(1):2956.

8.

Correction: Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.

Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, Giacomini PS, Antel J, Bar-Or A.

J Immunol. 2019 Apr 1;202(7):2172. doi: 10.4049/jimmunol.1900114. Epub 2019 Feb 15. No abstract available.

PMID:
30770414
9.

Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).

Johnen A, Bürkner PC, Landmeyer NC, Ambrosius B, Calabrese P, Motte J, Hessler N, Antony G, König IR, Klotz L, Hoshi MM, Aly L, Groppa S, Luessi F, Paul F, Tackenberg B, Bergh FT, Kümpfel T, Tumani H, Stangel M, Weber F, Bayas A, Wildemann B, Heesen C, Zettl UK, Zipp F, Hemmer B, Meuth SG, Gold R, Wiendl H, Salmen A; German Competence Network Multiple Sclerosis (KKNMS).

J Neurol. 2019 Feb;266(2):386-397. doi: 10.1007/s00415-018-9142-y. Epub 2018 Dec 4.

10.

Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk.

International Multiple Sclerosis Genetics Consortium. Electronic address: chris.cotsapas@yale.edu; International Multiple Sclerosis Genetics Consortium.

Cell. 2018 Nov 29;175(6):1679-1687.e7. doi: 10.1016/j.cell.2018.09.049. Epub 2018 Oct 18.

11.

GFAPα IgG-associated encephalitis upon daclizumab treatment of MS.

Luessi F, Engel S, Spreer A, Bittner S, Zipp F.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 13;5(5):e481. doi: 10.1212/NXI.0000000000000481. eCollection 2018 Sep.

12.

Regulation of IL-22BP in psoriasis.

Voglis S, Moos S, Kloos L, Wanke F, Zayoud M, Pelczar P, Giannou AD, Pezer S, Albers M, Luessi F, Huber S, Schäkel K, Kurschus FC.

Sci Rep. 2018 Mar 23;8(1):5085. doi: 10.1038/s41598-018-23510-3.

13.

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.

Graetz C, Gröger A, Luessi F, Salmen A, Zöller D, Schultz J, Siller N, Fleischer V, Bellenberg B, Berthele A, Biberacher V, Havla J, Hecker M, Hohlfeld R, Infante-Duarte C, Kirschke JS, Kümpfel T, Linker R, Paul F, Pfeuffer S, Sämann P, Toenges G, Weber F, Zettl UK, Jahn-Eimermacher A, Antony G, Groppa S, Wiendl H, Hemmer B, Mühlau M, Lukas C, Gold R, Lill CM, Zipp F.

Mult Scler. 2019 Apr;25(5):661-668. doi: 10.1177/1352458518763541. Epub 2018 Mar 13.

PMID:
29532745
14.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

15.

Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing-remitting multiple sclerosis.

Kroth J, Ciolac D, Fleischer V, Koirala N, Krämer J, Muthuraman M, Luessi F, Bittner S, Gonzalez-Escamilla G, Zipp F, Meuth SG, Groppa S.

Mult Scler. 2019 Mar;25(3):338-343. doi: 10.1177/1352458517748474. Epub 2017 Dec 11.

PMID:
29226779
16.

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.

Fleischer V, Friedrich M, Rezk A, Bühler U, Witsch E, Uphaus T, Bittner S, Groppa S, Tackenberg B, Bar-Or A, Zipp F, Luessi F.

Mult Scler. 2018 Apr;24(5):632-641. doi: 10.1177/1352458517703799. Epub 2017 Apr 24.

PMID:
28436295
17.

Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis.

Ghadiri M, Rezk A, Li R, Evans A, Luessi F, Zipp F, Giacomini PS, Antel J, Bar-Or A.

Neurol Neuroimmunol Neuroinflamm. 2017 Mar 23;4(3):e340. doi: 10.1212/NXI.0000000000000340. eCollection 2017 May.

18.

Dimethyl Fumarate Therapy Significantly Improves the Responsiveness of T Cells in Multiple Sclerosis Patients for Immunoregulation by Regulatory T Cells.

Schlöder J, Berges C, Luessi F, Jonuleit H.

Int J Mol Sci. 2017 Jan 28;18(2). pii: E271. doi: 10.3390/ijms18020271.

19.

Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.

Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, Giacomini PS, Antel J, Bar-Or A.

J Immunol. 2017 Jan 15;198(2):691-698. doi: 10.4049/jimmunol.1601649. Epub 2016 Dec 14. Erratum in: J Immunol. 2019 Apr 1;202(7):2172.

20.

NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk.

International Multiple Sclerosis Genetics Consortium. Electronic address: cotsapas@broadinstitute.org; International Multiple Sclerosis Genetics Consortium.

Neuron. 2016 Oct 19;92(2):333-335. doi: 10.1016/j.neuron.2016.09.052. Erratum in: Neuron. 2016 Nov 23;92(4):929.

Supplemental Content

Loading ...
Support Center